Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07458919) titled 'Therapy for Advanced NSCLC With EGFR 19delins Mutation' on March 1.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).

Primary Sponsor: Fuzhou General Hospital

Condition: Lung Cancer

Intervention: Drug: Icotinib/Gefitinib

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: March 30, 2026

Target Sample Size: 94

To know more, visit https://clinicaltrials.gov/study/NCT07458919

Published by HT Digital Content Services with permiss...